Danaher Corporation is a global science and technology company that designs, manufactures, and markets a diverse range of industrial and healthcare products and solutions
The company's operations are organized into several segments, including life sciences, diagnostics, dental, and environmental and applied solutions. Danaher focuses on advancing vital sciences and technologies through innovative products and services that enhance the quality of life. With a commitment to customer satisfaction, the company leverages its extensive expertise in engineering and manufacturing to deliver reliable and efficient solutions across various industries, helping to drive improved outcomes in healthcare, environmental monitoring, and industrial processes.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Thermo Fisher (NYSETMO) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Danaher (NYSEDHR) and the best and worst performers in the research tools & consumables industry.
Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher.
Repligen reported Q4 EPS of $0.44, beating estimates, with revenue of $167.55 million. The company projects 2025 sales of up to $710 million as the market recovers.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But near-term speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.
This has capped returns as the industry’s six-month gain of 1.2% has lagged the S&P 500’s 12.8% climb.
Diversified science and technology company Danaher (NYSEDHR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.1% year on year to $6.54 billion. Its non-GAAP profit of $2.14 per share was 1.3% below analysts’ consensus estimates.
Total earnings for the 112 S&P 500 companies that have reported results are up +10.8% from the same period last year on +5.5% higher revenues, with 80.4% beating EPS estimates and 68.8% beating revenue estimates.
